+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.

Age: 18Years +All GendersPhase 3
287 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active ulcerative colitis, a chronic condition causing inflammation and ulcers in the colon lining. This phase 3, randomized, double-blind, active-controlled study aims to assess how well these treatments work by measuring clinical remission at Week 48. Participants receive either JNJ-78934804 or guselkumab through subcutaneous injections. Both treatments begin with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks starting at Week 12. Participants who meet rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, with maintenance continuing every 4 weeks from Week 28. Those completing the initial 48-week treatment phase and deemed to benefit may join a long-term extension phase. Throughout the study, participants undergo assessments including endoscopic evaluations, clinical remission status, symptom scores, quality of life questionnaires, and safety monitoring for adverse events up to approximately 3 years. The primary outcome is the percentage of participants achieving clinical remission at Week 48, with multiple secondary outcomes measured at various time points. This comprehensive evaluation helps understand the treatment effects and safety profile over time.

Age: 18Years +All GendersPhase 3
318 locations
S

Actively Recruiting

Breast cancer is the most common cancer diagnosed in women in Europe, representing 29% of cases, with a 5-year survival rate around 90%. Treatment often includes surgery, radiotherapy RT, anthracyclines, aromatase inhibitors, and trastuzumab Herceptin, which have improved survival. However, RT can lead to various cardiovascular diseases, a leading cause of non-cancer death among these patients. New RT techniques have reduced heart radiation exposure, but their impact on cardiovascular risks is not yet known. This observational study follows two groups of breast cancer patients one treated with conventional RT between 2007 and 2012, and another treated with laser-assisted breath-controlled RT between 2015 and 2017. Both groups may have also received anthracyclines andor trastuzumab. The study includes age-matched female controls from the general population to compare cardiovascular outcomes over 15 years. Participants will be monitored for the incidence and prevalence of cardiovascular diseases at 8 and 15 years after RT. Researchers will use cardiac magnetic resonance imaging, coronary fractional flow reserve, ECG, and biomarkers to detect acute heart toxicity and assess its ability to predict later cardiovascular problems. Traditional risk factors like age, hypertension, cholesterol, smoking, and physical activity before RT will also be evaluated throughout the study.

Age: 30Years - 70YearsFEMALE
2 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of two antibiotic treatment strategies for adults hospitalized with suspected community-acquired sepsis. The study compares empirical combination therapy using gentamicin with narrow spectrum betalactams penicillin, ampicillin, or cloxacillin against empirical therapy with broad spectrum betalactams cefotaxime or piperacillin-tazobactam. The goal is to determine if the combination therapy is as safe as broad spectrum therapy, particularly regarding kidney injury and death, while also examining its impact on antibiotic resistance and the gut microbiome. Participants are randomly assigned to receive either gentamicin plus a narrow spectrum betalactam or one of the broad spectrum betalactams as empirical treatment for suspected sepsis. Treatments are given according to hospital protocols during the initial management of sepsis. The study is designed as a pragmatic clinical trial with parallel groups and does not use blinding. The investigation spans up to 30 days after randomization for primary outcomes, with follow-up during the hospital stay and after discharge. During the study, participants are monitored for various outcomes including 30-day mortality, acute kidney injury within 30 days, duration of hospital and intensive care stays, ventilator and vasopressor therapy use, hospital readmissions, and antibiotic treatment duration. Safety and treatment effects are assessed through clinical observations and data collected during hospitalization and up to 30 days after discharge. The total participation time covers the initial hospital treatment period and the 30-day follow-up after randomization.

Age: 18Years +All GendersPhase 4
15 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are studying the effects of antibiotics in children aged 9 to 36 months who have chronic wet cough CWC. This study is a phase 4, double-blind, placebo-controlled, randomized trial conducted across multiple centers nationwide. The goals are to understand how effective antibiotics are in treating CWC, whether the length of antibiotic treatment affects recovery or relapse, and to explore the role of respiratory pathogens, microbiomes, inflammation, immunology, and genetics in these children compared to healthy controls. The study consists of two randomized controlled trials, AMIC 1 and AMIC 2. In AMIC 1, 90 children will be randomly assigned to receive either amoxicillin-clavulanate syrup or a placebo syrup for 14 days. In AMIC 2, 210 children will be randomly assigned to receive either 14 days of amoxicillin-clavulanate with 14 days of placebo or a full 28 days of the antibiotic syrup. Additionally, 50 healthy children will be included for comparison and will have two visits spaced six months apart. During the study, children will be followed for up to 24 months after starting treatment to assess response and relapse of symptoms. Researchers will evaluate treatment response 14 days after antibiotic completion and monitor for any relapse up to two years later. Assessments include cough scoring, microbiome analysis from airway and gut samples, and examination of inflammation, immunology, and genetics. The study also involves regular monitoring to ensure safety and adherence to treatment protocols throughout the trial period.

Age: 9Months - 36MonthsAll GendersPhase 4
7 locations
C

Actively Recruiting

Researchers are evaluating whether a shorter period of immunotherapy after radical surgery is as effective as the standard longer treatment for patients with high-risk malignant skin melanoma. This study focuses on people aged 18 and older who have undergone surgery for stage IIb-c, III, or IV melanoma. The goal is to see if six months of immunotherapy can prevent cancer recurrence as well as the current 12-month treatment, potentially reducing side effects, hospital visits, and healthcare costs. The study is a randomized phase 3 trial conducted internationally with patients followed for up to five years. Participants will receive immunotherapy drugs, currently nivolumab or pembrolizumab, given intravenously. They are randomly assigned to either six months experimental group or 12 months standard group of treatment. Patients who had immunotherapy before surgery neoadjuvant treatment can also join, with their pre-surgery treatment time added to the post-surgery treatment. Medical exams and imaging scans CT or PET-CT are done at the start, six months, and 36 months, along with regular check-ups over three years. If cancer returns, additional tests and treatments are planned based on medical team decisions. During the study, participants will have scheduled visits for physical exams, blood tests, and scans to monitor their health and detect any recurrence. Researchers will measure relapse-free survival and distant metastatic-free survival at two years as primary outcomes, with overall survival and health economic effects also assessed over five years. Safety monitoring includes standard care practices and follow-up for up to five years. The study aims to confirm if shorter immunotherapy duration maintains the same outcomes while benefiting patients and healthcare systems.

Age: 18Years +All GendersPhase 3
26 locations
S

Actively Recruiting

This research aims to study patients who have undergone surgery for carpal tunnel syndrome CTS at lesund Hospital to identify the presence of ATTR amyloidosis through biopsy. The study focuses on patients with biopsy-confirmed ATTR amyloidosis, assessing whether they have cardiac amyloidosis and monitoring them closely over a long term. The study is observational and plans to follow participants for up to 10 years to understand the frequency of ATTR in CTS and cardiac involvement. Patients with biopsy-proven ATTR amyloidosis will undergo standard examinations recommended by guidelines, including 99mTcDPD SPECT CT, echocardiography, ECG, Holter monitoring, genetic testing for variant and wild type ATTR, laboratory tests, and CMRI when indicated. Light chain disease will be excluded. All patients will be monitored at least annually following established guidelines, and those developing cardiac amyloidosis will receive standard treatments approved by Norwegian authorities. Participants will be followed clinically and with echocardiography yearly for at least 10 years. Assessments include imaging, genetic testing, and laboratory evaluations to track disease progression and cardiac involvement. The primary outcome measures are the frequency of ATTR in CTS within 2 years and cardiac involvement in patients with biopsy-confirmed ATTR over 10 years. This extended follow-up aims to provide comprehensive data on the long-term impact of ATTR amyloidosis in this selected population.

Age: 50Years +All Genders
1 location
P

Actively Recruiting

Researchers are evaluating the use of specific molecular biomarkers to personalize treatment for patients with endometrial cancer. This study focuses mainly on biomarkers found promising in previous research and aims to improve surgical and medical treatment decisions. The trial has two parts one tests the use of biomarkers to guide lymphadenectomy during surgery, and the other assesses the biomarker stathmins potential to predict response to taxane chemotherapy in endometrial and ovarian cancer. The study includes an implementation phase where lymphadenectomy is performed based on hormone receptor status ER and PR to define patient risk and guide surgery. Patients considered low risk based on tumor grade and receptor status may avoid lymphadenectomy, while higher-risk patients undergo pelvic and para-aortic lymphadenectomy. In the second phase, patients receiving weekly taxane treatment have tissue biopsies and urine samples analyzed for stathmin levels before and during treatment. Imaging scans and blood tests are conducted regularly to monitor disease progression. Participants will receive routine clinical follow-up for five years, including quality of life questionnaires. Researchers will collect data on survival, disease recurrence, and quality of life over this period. For patients in the taxane treatment phase, urine and blood samples will be collected weekly, with imaging every eight treatment cycles. The studys main outcomes include the number of cancer recurrences after five years and the duration of treatment response in metastatic disease, along with correlations of stathmin levels in various samples.

Age: 18Years - 95YearsFEMALEPhase 4
9 locations
R

Actively Recruiting

Researchers are evaluating the benefits and risks of using furosemide, a diuretic, compared to a placebo in critically ill adult patients who experience fluid overload in the intensive care unit ICU. Fluid overload, a common complication in ICU patients, can worsen outcomes especially in those with acute kidney injury. The study aims to determine if reducing excess fluid with furosemide improves patient health or if fluid overload is simply a marker of severe illness. Participants are randomly assigned to receive either furosemide or a placebo isotonic saline through intravenous infusion. The furosemide group receives a bolus dose followed by an infusion adjusted to target a negative fluid balance of 1 ml per kg per hour, with fluid balance monitored three times daily. The placebo group receives saline dosed and adjusted by the same protocol. Treatment continues until the excess fluid is removed and fluid balance is neutral. During the study, participants will be closely monitored for fluid balance and clinical stability. Researchers will assess outcomes including days alive and out of hospital within 90 days, mortality rates up to one year, serious adverse events, quality of life, and cognitive function. The study involves a randomized, blinded design to compare the effects of furosemide versus placebo over a one-year follow-up period.

Age: 18Years +All GendersPhase 4
29 locations
N

Actively Recruiting

Researchers are investigating the role of deferred cytoreductive nephrectomy compared with no surgery in patients with synchronous metastatic renal cell carcinoma mRCC who have intermediate or poor risk features according to the International Metastatic Renal Cell Carcinoma Database Consortium IMDC. The study evaluates the impact of surgery timing after initial treatment with immune checkpoint inhibitors, such as nivolumab combined with ipilimumab, or a tyrosine kinase inhibitor TKI combined with immunotherapy, aiming to improve overall survival in this patient group. Participants receive induction immunotherapy immediately after enrollment, consisting of four series of nivolumab combined with ipilimumab or a TKIIO combination over three months. After this induction, patients are assessed for eligibility for surgery by a multidisciplinary team. Those with three or fewer IMDC risk factors and deemed suitable for surgery are randomized to either deferred nephrectomy followed by maintenance therapy or maintenance therapy alone. Patients not eligible for surgery or with more than three risk factors continue systemic therapy and are reevaluated at six months. Treatment with nivolumab may continue for up to two years or until unacceptable toxicity. During the study, tumor tissue, blood, and stool samples are collected at baseline, three months, and six months for research purposes. Outcomes being measured include overall survival with a minimum follow-up of three years, progression-free survival, response rates, treatment-related side effects, surgical complications, and various biomarker analyses. Participants will be monitored regularly throughout treatment and follow-up, with the study lasting through to the planned completion date in 2031.

Age: 18Years +All GendersPhase Not Applicable
11 locations

1-10 of 26

1